About Marinomed Biotech
Marinomed Biotech AG (Korneuburg, Austria) (VSE:MARI) is an Austrian science-based biotech company with globally marketed therapeutics. The company is listed on the Prime Market of the Vienna Stock Exchange. Marinomed focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv® technology increases the solubility and bioavailability of compounds that are hardly soluble in aqueous formulations. The Carragelose® platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and may also reduce the risk of an infection with SARS-CoV-2. Carragelose® is used as a virus blocker in nasal sprays, throat sprays, and lozenges, which are sold via international partners in over 40 countries.
- Founding: 2006
- Focus : Service
- Employees: 11-50
- Industry : Biotechnology, Pharma
News about Marinomed Biotech
20-Jul-2020 | research and development
Carragelose effective against SARS-CoV-2 in cell culture assays
Marinomed is now planning clinical tests using the same technology for an inhalation solution that could also work in the lungs
29-Apr-2020 | business & finance
Marinomed receives funding to research SARS-CoV-2 therapy
Marinomed Biotech AG receives funding from the Austrian Research Promotion Agency (FFG) for the development of a SARS-CoV-2 therapy based on Carragelose®. ...
21-Nov-2012 | research and development
Marinomed Granted Chinese Patent for Antiviral Polymer
Marinomed Biotechnologie GmbH announced that it has been granted Chinese Patent No. CN101678040, entitled ‘Antiviral polymer’, by the Chinese patent office ...
24-Nov-2010 | business & finance
Marinomed wins STEP award in "Market/Customer" category and special award for strategic partnerships
Marinomed Biotechnologie GmbH announced that it has won the €10,000-endowed Step Award 2010 in the "Market/ Customer” category. Marinomed also received an ...
01-Jul-2010 | business & finance
Marinomed Signs Collaboration with Boehringer Ingelheim for Anti-Viral Nasal Spray Against Common Cold
Marinomed Biotechnologie GmbH announced that it has signed a licensing agreement with Boehringer Ingelheim. The deal will aim to further extend marketing ...
28-May-2010 | research and development
Marinomed’s MAM-06.301 achieves preclinical proof of concept
Marinomed Biotechnologie GmbH announced that MAM-06.301 has achieved preclinical proof of concept for the treatment of allergy and allergic asthma. The ...
15-Mar-2010 | research and development
Marinomed Granted European Patent for Anti-Viral Active Ingredient
A core component of Marinomed’s respiratory technology platform